Richard L. Ehman

Sequential FIB-4–based testing limits detection of fibrotic MASLD despite optimized ELF thresholds

Background: Societal guidance recommends sequential noninvasive testing for metabolic dysfunction–associated steatotic liver disease (MASLD), using Fibrosis-4 (FIB-4) ≥1.3 as a gatekeeper before second-line assessment with the Enhanced Liver Fibrosis (ELF) score (<7.7 as a rul...